BioCentury | Jul 11, 2016
Company News

Uni-Bio Science Group, China Resources Pharmaceutical deal

...Uni-Bio granted exclusive, Chinese commercialization rights to GeneSoft to the China Resources Zizhu Pharmaceutical Co. Ltd...
...to GeneSoft for five years, with an option to renew for an additional five years. GeneSoft...
BioCentury | Jun 28, 2016
Company News

Zizhu gets China rights to Uni-Bio's eye drug

...Science Group Ltd. (HKSE:690) said it granted exclusive commercialization rights in China to ophthalmology treatment GeneSoft...
...to GeneSoft for five years, with an option to renew for an additional five years. GeneSoft...
BioCentury | Feb 8, 2010
Strategy

Out from Down Under

...development of many FDA-approved products while at SmithKline Beecham plc (now GlaxoSmithKline plc ) and Genesoft Pharmaceuticals Inc....
BioCentury | Sep 18, 2006
Product Development

FDA's superior attitude

...2003, the anti-infectives panel recommended approval for these indications, which FDA granted the next month. GeneSoft...
...met all primary and secondary endpoints," Gary Patou, a board director and former president of GeneSoft...
BioCentury | May 2, 2005
Finance

Going big

...Series C $108.5 Biovitrum (A)(B) 8/1/01 Series A $85.0 Perlegen (B) 2/28/05 Series D $74.0 Genesoft...
BioCentury | Jul 26, 2004
Strategy

RAVE goodbye and move on

...wall synthesis, from Vicuron Pharmaceuticals Inc. (MICU; NMerc:MICU, King of Prussia, Penn.). In April 2003, Genesoft Pharmaceuticals Inc....
...acute bacterial exacerbation of chronic bronchitis (ABECB) and mild to moderate community-acquired pneumonia (CAP). However, Genesoft...
...in the fourth quarter. Enrollment is expected to be complete in the summer of 2005. Genesoft...
BioCentury | May 10, 2004
Finance

Ebb & Flow

...offering in February. That financing came as GENE (formerly Genome Therapeutics) completed its merger with Genesoft...
BioCentury | May 5, 2004
Financial News

Oscient raises $125 million

...to treat acute bacterial exacerbations of chronic bronchitis. GENE acquired Factive from its merger with Genesoft...
BioCentury | May 3, 2004
Financial News

Oscient proposes $75 million note deal

...to treat acute bacterial exacerbations of chronic bronchitis. GENE acquired Factive from its merger with Genesoft...
BioCentury | Apr 13, 2004
Company News

GENE changes name to Oscient

...GENE) changed its name to Oscient , a move that follows GENE's February merger with Genesoft...
Items per page:
1 - 10 of 48
BioCentury | Jul 11, 2016
Company News

Uni-Bio Science Group, China Resources Pharmaceutical deal

...Uni-Bio granted exclusive, Chinese commercialization rights to GeneSoft to the China Resources Zizhu Pharmaceutical Co. Ltd...
...to GeneSoft for five years, with an option to renew for an additional five years. GeneSoft...
BioCentury | Jun 28, 2016
Company News

Zizhu gets China rights to Uni-Bio's eye drug

...Science Group Ltd. (HKSE:690) said it granted exclusive commercialization rights in China to ophthalmology treatment GeneSoft...
...to GeneSoft for five years, with an option to renew for an additional five years. GeneSoft...
BioCentury | Feb 8, 2010
Strategy

Out from Down Under

...development of many FDA-approved products while at SmithKline Beecham plc (now GlaxoSmithKline plc ) and Genesoft Pharmaceuticals Inc....
BioCentury | Sep 18, 2006
Product Development

FDA's superior attitude

...2003, the anti-infectives panel recommended approval for these indications, which FDA granted the next month. GeneSoft...
...met all primary and secondary endpoints," Gary Patou, a board director and former president of GeneSoft...
BioCentury | May 2, 2005
Finance

Going big

...Series C $108.5 Biovitrum (A)(B) 8/1/01 Series A $85.0 Perlegen (B) 2/28/05 Series D $74.0 Genesoft...
BioCentury | Jul 26, 2004
Strategy

RAVE goodbye and move on

...wall synthesis, from Vicuron Pharmaceuticals Inc. (MICU; NMerc:MICU, King of Prussia, Penn.). In April 2003, Genesoft Pharmaceuticals Inc....
...acute bacterial exacerbation of chronic bronchitis (ABECB) and mild to moderate community-acquired pneumonia (CAP). However, Genesoft...
...in the fourth quarter. Enrollment is expected to be complete in the summer of 2005. Genesoft...
BioCentury | May 10, 2004
Finance

Ebb & Flow

...offering in February. That financing came as GENE (formerly Genome Therapeutics) completed its merger with Genesoft...
BioCentury | May 5, 2004
Financial News

Oscient raises $125 million

...to treat acute bacterial exacerbations of chronic bronchitis. GENE acquired Factive from its merger with Genesoft...
BioCentury | May 3, 2004
Financial News

Oscient proposes $75 million note deal

...to treat acute bacterial exacerbations of chronic bronchitis. GENE acquired Factive from its merger with Genesoft...
BioCentury | Apr 13, 2004
Company News

GENE changes name to Oscient

...GENE) changed its name to Oscient , a move that follows GENE's February merger with Genesoft...
Items per page:
1 - 10 of 48